A distinct clinical subgroup of nonsmoking (NS) and nondrinking (ND) patients with oral squamous cell carcinoma (OSCC) has been identified. The objective of the study was to assess this cohort for molecular variations in the disease process and if these could be attributed to clinical or epidemiological characteristics. One hundred and twenty-nine consecutive patients (71 males, 58 females) treated for OSCC were assessed at the Royal Melbourne Hospital between January 2007 and July 2010. Formalin-fixed paraffin embedded (FFPE) sections were stained for p53, p16, cyclin D1, and epidermal growth factor receptor (EGFR). Biomarker overexpression was observed in 72 (56%) cases for p53, 23 (18%) for p16, 45 (35%) for cyclin D1, and 72 (56%) for EGFR. Multiple logistic regression analysis revealed that tongue tumors (p ¼ 0.012) and late stage cancers (p ¼ 0.031) were more likely to have cyclin D1 overexpression. Further, older patients significantly more often had cyclin D1 overexpression (p ¼ 0.008) and NSND patients had more p16 expression (p ¼ 0.043). In contrast, smokers were more likely to have EGFR overexpression (p ¼ 0.033). Concurrent overexpression of p53 and cyclin D1 were observed (p ¼ 0.030). Smoking, site, and stage of OSCC can influence biomarker expression, with p16 overexpression specifically observed in NSND, indicating fundamental differences in the mechanisms of oral carcinogenesis among different patient cohorts.
Introduction
Oral squamous cell carcinoma (OSCC) is the sixth most prevalent malignancy globally. 1, 2 Chronic tobacco use and alcohol consumption are well-established prominent risk factors. [3] [4] [5] Oral cancer results in significant mortality and morbidity with severe impairment to quality of life, with the 5-year survival following diagnosis as low as 15-50% globally. 6, 7 Fundamental to this, a large proportion of these cancers are diagnosed at an advanced stage and have associated lymphatic spread, explaining the poor outcomes.
Recently, a distinct clinical subgroup of elderly female nonsmoking (NS) and nondrinking (ND) patients with OSCC has been reported, which may represent an increasing proportion of OSCC patients over time due to declines in tobacco use and aging of the population. [8] [9] [10] These investigators showed that this cohort had a different demographic distribution with worse outcomes. Currently, NSND population represents 13-35% of the OSCC population, with up to 24% of head and neck cancers being found in patients greater than 70 years of age. [11] [12] [13] [14] Over the last decade there has been much interest in molecular staging in cancer in a bid to improve patient management. Identification of relevant biomarkers may help in our understanding of oral carcinogenesis, have the potential to facilitate early diagnosis/detection of primary tumors, aid in the development of conservative therapies, and help in the prediction of disease progression and/or aggressiveness. 15, 16 Abnormal cell cycle regulation is one of the hallmarks of carcinogenesis; dysregulation not only leads to uncontrolled cellular proliferation but also contributes to escape from other checkpoints such as senescence and apoptosis. 17 Alterations in structure, function, or expression levels of proteins involved in cell cycle regulation are regarded to be important in the development and progression of head and neck cancer. 18 The tumor suppressor protein p53 plays a pivotal role in cell cycle progression, with loss of function strongly associated with malignancy. 19, 20 Cyclin D1 is also involved in cell cycle regulation (normal and neoplastic), allowing cells to progress from G1/S phase allowing the initiation of DNA replication. 21 P16 inhibits progression from G1/S phase via the inhibition of cyclin D1-mediated phosphorylation of retinoblastoma protein. 18, 22 The retinoblastoma pathway is crucial in regulating cell cycle progression; phosphorylation of retinoblastoma protein results in its functional inhibition and release of transcription factors required for cell cycle progression. 23 Epidermal growth factor receptor (EGFR) is a cell surface receptor for members of the family of epidermal growth factors, which activate tyrosine kinase signaling pathways resulting in cell proliferation, differentiation, and survival 24 ; overexpression has been described in various human malignancies. 25 This study's hypothesis was that OSCC in NSND have a unique molecular profile and that this is reflected in its immunohistochemistry (IHC) expression to a panel of biomarkers. A panel of target proteins (biomarkers) as described above (p53, p16, cyclin D1, and EGFR) was chosen as they have been previously shown to have a high expression in oral cancer. 26 
Methods

Patients
A previous study assessed 169 (97 males, 72 females) consecutive patients who presented with new or recurrent OSCC at the Royal Melbourne Hospital between January 2007 and July 2010. 9 Of the 169 patients diagnosed, 11 had no tissue available as their diagnostic biopsy was undertaken prior to admission. This project was approved by the Melbourne Health Human Research Ethics Committee on 19th September 2012 (MH Project number 2012.071).
Tissue samples
FFPE tumor tissue blocks were obtained for each of the 158 patients. A pathologist (author CA) identified the area that contained the most tumor tissues. A total of 24 specimens were further excluded from the project as 18 had no discernable cancer in the surgical specimen and 6 had insufficient tissues. Thus, a total of 134 specimens of the original 169 were included for IHC analysis. Sections were cut from each identified block for IHC staining. However, following IHC, five specimens were further excluded as no tumor tissues were observable. Thus, this study was a convenience sample of 129 consecutive patients who had a diagnosis of OSCC and well-characterized clinical features, including history and known etiological agents. The study group in question was NSND patients (n ¼ 32) with other OSCC patients (n ¼ 97) as controls.
IHC
IHC staining was performed to determine the expression of the chosen biomarkers (p53, p16, cyclin D1, and EGFR). Formalin-fixed paraffin-embedded tissues were sectioned at 4 mm thickness and sequentially dewaxed/deparaffinized through a series of xylene, graded alcohol, and water immersion steps and then rehydrated and treated with 3% hydrogen peroxide to block endogenous peroxidase. Antigen retrieval was performed for all antibodies using Leica Bond high pH retrieval solution (Cat. no. AR9640) for 20 min at 100 C with the Leica Bond III stainer (Leica Microsystems, Inc., Buffalo Grove, Illinois, USA). The sections were mounted onto superfrost plus slides and air-dried at 37 C overnight.
IHC staining was performed on the Leica Bond III automated IHC stainer (using Leica Bond detection kit Cat. no. DS9800), according to the manufacturers' instructions. The sections were equilibrated with neutralizing buffer (Leica wash buffer) and incubated for 15 min with primary antibodies. The primary antibodies and the dilutions used are shown in Table 1 . After incubation with primary antibodies for 15 min at room temperature, bound antibodies were detected using the Bond polymer refine detection system, a biotin-free, polymeric horseradish peroxidase-linker antibody conjugate system (Leica Microsystems), which contains a peroxide block, post primary, polymer reagent, 3,3 0 -diaminobenzidine tetrahydrochloride chromogen, and hematoxylin counterstain. Positive control slides were included for validation in order to minimize variation in each IHC batch run using tissue sections that were known to be positive or had an abundance of the specific antibody.
Quantitative IHC analysis
All slides were scanned at an absolute magnification of 400Â (resolution of 0.25 mm/pixel (100,000 pix/in.)) using the Aperio ScanScope XT system (Aperio Technologies Inc., Vista, California, USA). Slides were viewed and analyzed using Image-Scope 1 software package version 11.1.2.760 (Aperio Technologies Inc.) to quantify the IHC staining. All slides were coded and examined blindly. Three to five fields of view of representative areas of viable tumor of approximately the same size (0.025 mm 2 ) were chosen for analysis under high-power fields. The degree of staining for p53, p16, and cyclin D1 was assessed using the positive pixel count algorithm, and EGFR assessed using the membrane algorithm. This latter method was used for EGFR staining as this is predominantly localized to the cell membrane, whereas the other proteins were predominately localized to the nucleus. As the membrane algorithm was used to evaluate EGFR staining, we could not analyze the extent of cytoplasmic staining that was weak in the majority of our cases. To confirm the reproducibility, 25% of the slides were randomly chosen and scored twice. All duplicates were evaluated using the methods described. Figure 1 shows a representation for overexpression of each biomarker.
Statistical analysis
Raw data were initially collated into a Microsoft Excel spreadsheet and subsequently exported for all statistical analysis to the software package R (R Foundation for Statistical Computing, Vienna, Austria). Descriptive statistics were calculated for all variables.
For statistical analysis, the average positive pixel count result for each specimen was dichotomized and assigned one of two categories: negative/weak expression for scores of <20% and overexpression for scores >20% for p53, p16, and cyclin D1. For EGFR, the overall output score was categorized with scores of 0-2 assigned as negative/weak expression and a score of 3 assigned as overexpression (complete membrane staining).
The stage was classified according the American Joint Committee on Cancer sixth edition system and dichotomized for statistical analysis, with stages I and II classified as ''early stage'' and stages III and IV classified as ''late stage.'' Mortality data were sourced from both the ACCORD and the Victorian Cancer Registry databases, with a minimum follow-up of 18 months (census date January 1, 2012), including diseasespecific mortality. Disease-free survival was recorded from the clinical follow-up notes.
Univariate analysis was performed using the w 2 test to assess the relationship between the epidemiological and clinical factors for each biomarker overexpression. Multivariate logistic regression analysis was then undertaken to identify the best set of predictors by estimation of the odds ratio (OR) and 95% confidence interval. Survival data (disease-free survival) for each biomarker was performed univariately with the Kaplan-Meier product limit method. The log-rank test was used to compare survival outcomes for statistical analysis. A p value of 0.05 was considered as significant.
Results
Patient characteristics
The study population consisted of 71 (55%) males and 58 (45%) females; 79 (61%) were less than 70 years of age and 50 (39%) were 70 years or older; 73 (57%) patients were smokers and 56 (43%) were nonsmokers (which included those with <5 pack years); 84 (65%) consumed alcohol (which included <3 drinks per week), with 45 (35%) being nondrinkers. The site was dichotomized and classified as tongue (comprising only cases from the anterior one-third or anterior to the foliate papillae) or nontongue (nontongue comprising mandibular and maxillary alveolus, retromolar region, floor and vestibule of mouth, hard palate, and cheek mucosa), with 49 (38%) of tumors originating from the tongue and the remaining 80 (62%) from nontongue; 72 (56%) patients had ''early stage'' OSCC, and those with ''late stage'' comprised 57 (44%) patients. A total of 38 (29%) patients' deaths were due to OSCC. Table 2 provides a detailed summary of the clinicopathological characteristics analyzed. All tumors originated from the oral cavity (none were from the oropharyngeal region). No patients in this cohort were diagnosed with proliferative verrucous leukoplakia.
Statistical analysis of the demographics of these patients showed that there were statistically significantly more males who consumed alcohol (
to females. There were statistically significant more patients under the age of 70 years who consumed alcohol (w 2 ¼ 6.2, df ¼ 1, p value ¼ 0.013) and were smokers (w 2 ¼ 7.1, df ¼ 1, p value ¼ 0.008) compared to patients over the age of 70 years; but with death caused by OSCC occurring more in patients over the age of 70 years (w 2 ¼ 10.8, df ¼ 1, p value ¼ 0.001). Later stage cancers were those of tongue origin (w 2 ¼ 10.0, df ¼ 1, p value ¼ 0.002), with smokers also having significantly more tongue tumors (
Smoking was significantly associated with alcohol consumption, as expected (w 2 ¼ 21.6, df ¼ 1, p value 0.001).
Comparisons between the NSND group (n ¼ 32 (25%)) and all other patients (n ¼ 97 (75%)) found that the NSND cohort had statistically significant more females (w 2 ¼ 18.9, df ¼ 1, p value 0.001), a significantly greater proportion of individuals over the age of 70 years (w 2 ¼ 12.9, df ¼ 1, p value ¼ 0.001) who had more tongue tumors (w 2 ¼ 4.1, df ¼ 1, p value ¼ 0.042).
These results indicated that our cohort (n ¼ 129) was representative of the initial cohort (n ¼ 169) in that there were more females over the age of 70 years with tongue tumors, with a greater proportion of NSND as described previously. 9 
Biomarker expression
Overexpression of the biomarkers investigated was seen in 72 (56%) patients for p53, 23 (18%) for p16, 45 (35%) for cyclin D1, and 72 (56%) for EGFR. Tables 3 and 4 show the correlation of biomarkers with clinicopathological parameters. Patients who were less than 70 years of age had overexpression of cyclin D1 (w 2 ¼ 10.2, df ¼ 1, p ¼ 0.001). Patients with later stage OSCC more often had higher levels of cyclin D1 and patients with tongue tumors also had higher levels of cyclin D1 overexpression, however, these differences did not reach statistical significance (w 2 ¼ 3.6, df ¼ 1, p value ¼ 0.057; w 2 ¼ 3.5, df ¼ 1, p value ¼ 0.062, respectively). Multiple logistic regression was undertaken to assess all epidemiological and clinical factors (gender, age, smoking status, drinking status, site, and stage of OSCC) for important predictor variables of biomarker overexpression to enable quantitative comparison of their separate and joint effects as indicated by the OR. Logistic regression was performed for each biomarker using backward stepwise regression after testing for any possible interactions among independent variables to eliminate the influence of confounders, with the best fit model used to determine the risk factors for each biomarker expression. Two separate models were assessed, the first for all patients and the second assessing the NSND cohort. In the model assessing all patients, no Tongue  19  30  37  12  27  22  18  31  Nontongue  38  42  69  11  57  23  39  41  Stage  Early  31  41  59  13  52  20  32  40  Late  26  31  47  10  32  25  25  32  Death from oral cancer  No  42  49  73  18  62  29  43  48  Yes  15  23  33  5  22  16  14  24 EGFR: epidermal growth factor receptor. a ''Negative'' refers to no/weak expression and ''positive'' refers to overexpression. Results assessing the interactions of cyclin D1 with younger (<70 years), late stage, and tongue tumors showed that patients with late stage and tongue tumors (n ¼ 10) were 9.9Â more likely to have cyclin D1 overexpression (OR ¼ 9.93, CI ¼ 2.58-51.07, p ¼ 0.002). Patients who were younger with late stage tongue tumors (n ¼ 7) were 15.2Â more likely to have cyclin D1 expression (OR ¼ 15.23, CI ¼ 2.59-291.08, p ¼ 0.012). These patients also trended toward better survival compared to all other patients with cyclin D1 overexpression, however, this was not statistically significant (Figure 2(d) ).
Finally, multiple logistic regression was performed to identify correlations between biomarkers. From this it was found that p53 and cyclin D1 overexpression was significantly associated (OR ¼ 2.32, CI ¼ 1.10-5.09, p ¼ 0.031).
The mean follow-up time for all patients was 28 months (range:18-64 months). Thirty-eight patients had died from oral cancer by the census date due to oral cancer. Kaplan-Meier curves were plotted from survival data. Analysis of all biomarker expression (log rank test) showed that none were statistically significantly associated with survival. The NSND cohort had a higher disease-specific mortality than the rest of the patient cohort, but this did not reach significance (p ¼ 0.166; Figure 2(a) ). However, poorer survival was seen in patients with p16 overexpression (Figure 2(b) ); while in those that lacked p16 overexpression, the NSND cohort had lower survival (Figure 2(c) ), however, neither reached significance (p ¼ 0.084; p ¼ 0.089, respectively).
The NSND cohort, consisting of 32 patients, also showed an increase in p16 overexpression in younger patients. Post hoc analysis was undertaken on the patients who had weak/no expression of p16, as it was felt that these individuals might be confounding the remaining analyses. Patients who were less than 70 years of age and those with tongue tumors had overexpression of cyclin D1 (w 2 ¼ 7.5, df ¼ 1, p ¼ 0.006; w 2 ¼ 6.3, df ¼ 1, p ¼ 0.012, respectively). NSND patients also had an overexpression of cyclin D1 (w 2 ¼ 10.7, df ¼ 1, p value ¼ 0.001) but weak/no expression of p53, however, this difference did not reach statistical significance (w 2 ¼ 3.6, df ¼ 1, p value ¼ 0.058).
Logistic regression further showed that cyclin D1 overexpression occurred statistically significantly more commonly in patients less than 70 years of age (OR ¼ 3.94, 95% CI ¼ 1.57-10.92, p ¼ 0.005) and in those with tongue tumors (OR ¼ 3.33, 95% CI ¼ 1.37-8.42, p ¼ 0.009). The model assessing EGFR showed that EGFR overexpression was statistically significantly more common in smokers (OR ¼ 2.41, 95% CI ¼ 1.05-5.73, p ¼ 0.041).
Discussion
Koo et al. 9 have demonstrated that NSND patients with OSCC comprise significantly more females over the age of 70, with the tongue as the predominant site of tumors that show poorer outcomes. Oral cancer has been traditionally found in males who smoke and drink, with the ratio of male to females in Australia previously reported as 2.5-3:1. 27 The cohort in the present study showed a male to female ratio to be 1.3:1. The aim of the present study was to assess this cohort for molecular variations in the disease process and if these could be attributed to clinical or epidemiological characteristics. Early detection remains to be the most promising approach to improve the long-term survival of patients with OSCC; biomarkers may provide important prognostic information for the management of patients with OSCC.
Overexpression of p53 was found in 56% of OSCC in the present study. This was consistent with the study by Bosari and Viale 28 who found that p53 expression in OSCC ranges from 37% to 78%. Furthermore, they reported that there was no correlation with clinicopathological variables, which is in agreement with our present study. Carlos de Vicente et al. 29 also showed inconclusive results when investigating if p53 immunoexpression influenced the clinical outcome of OSCC. They concluded that the ambiguity of results in the literature was attributed to a variety of factors including small and heterogeneous patient samples, tissue type analyzed (frozen and paraffin-embedded) and its pretreatment, antibodies applied, and the arbitrary threshold of the percentage of stained cells used to characterize sections as positive. 29 Cyclin D1 overexpression was found in 35% of patients in this study, which is similar to Shintani et al. 30 finding detection rates of 35.9%, with overexpression ranging between 39% and 83%. Later stage cancers were significantly more likely to have overexpression compared to earlier stages (p ¼ 0.037) after adjusting for all other clinicopathological parameters in multivariate logistic analysis. This is in agreement with Sathyan et al. 31 and Huang et al. 32 who found that cyclin D1 overexpression was associated with stage, but not with the age, of onset. Other studies have shown no significant correlation between cyclin D1 overexpression and clinicopathological factors. 33, 34 However, we found that patients !70 years of age were less likely to have cyclin D1 overexpression compared with those <70 years of age (p ¼ 0.004). This may suggest that there are different mechanisms involved in tumor progression between younger and older patients.
The site of the tumor was also a predictor of cyclin D1 overexpression, with tongue tumors having an increased risk compared to other sites (p ¼ 0.012), supporting the findings by Haas et al. 35 This finding suggests that OSCC originating in different sites of the oral cavity may behave differently. Other clinicoepidemiological studies show tongue cancer behavior is different from other sites of origin, but reasons for such difference are lacking in the literature. 31 Our results indicate that OSCC of different anatomical subsites are actually characterized by alterations at different pathways.
EGFR was found in 56% of patients, a result aligned with previous reports. 36 Therapeutic agents targeting EGFR, including EGFR inhibitor cetuximab, have been developed with promising results, 37 however, clinical information concerning its status in OSCC is limited and varied. Ryott et al. 38 found no correlation with EGFR status and survival, but significant expression in advanced tumors (stages II, II, and IV), and that nonsmokers with tongue cancers had a higher expression in early stages (I and II) compared to smokers. However, Kumar et al. 39 found smoking was significantly associated with EGFR expression, and these patients with oropharyngeal cancers had the worst overall survival. This is supported by Moraitis et al. 40 who found that EGFR ligand levels are increased in the oral mucosa of smokers. These latter findings therefore are in accordance with the result of the present study in that smokers were found to have a statistically significant increased risk of EGFR overexpression (p ¼ 0.032).
P16 overexpression was found in 18% of the patients, with 16% of the NSND cohort having p16 overexpression. p16 has been reported to show a significant correlation with head and neck cancers in nonsmokers, specifically for patients whose cancers originated in the tonsils. 35 In the present study, we found that in the NS and ND cohort there was a significant association between p16 overexpression in those <70 years. This may suggest that tumors in those <70 years are genetically distinct. Su et al. 41 found that hypermethylated p16 promoter was associated with regional invasiveness, distant metastasis, and reduced life span in elderly patients, suggesting that the molecular carcinogenic mechanism of p16 might be related in part to aging. However, criticizing this study Shaw et al. 42 have suggested that due to the small sample size and great risk of type I error, their results should not go unchallenged, as other studies have shown that p16 methylation was associated with OSCC presence but not poor prognosis. 43, 44 The p16 IHC has been used as a surrogate marker for human papillomavirus (HPV) infection in oropharyngeal cancer. [45] [46] [47] [48] Duncan et al. 1 found that strong staining for p16 correlated with HPV positivity in OSCC. However, others have found no correlation between p16 overexpression and the presence of HPV. 3, 5 HPVassociated cancers have been shown to be less likely to occur among drinkers and smokers, 6 and further oral tongue cancers had no significant association with HPV. 8, 10 The results of the present study indicate that there may be a cohort of younger, NSND patients with oral cancer caused by HPV. Further investigation such as polymerase chain reaction (PCR) or in-situ hybridization, would be needed to confirm the presence of HPV, as the evidence for the association between p16 overexpression and HPV infection is conflicting.
Analysis of survival rates showed there was a higher disease-specific mortality in the NSND cohort (Figure 2(a) ) and p16 overexpression cohort (Figure 2(b) ). Those who were nonsmokers and nondrinkers and were p16 negative had higher disease-specific mortality (Figure 2(c) ). This finding is contrary to previous reports, which have reported that those with p16 overexpression tend to have better outcomes and overall survival. 11, 13, 14 However, these studies assessed both oral cavity and oropharyngeal squamous cell carcinoma, and it may well be that patients with p16-positive oral cavity tumors have a far worse progression than p16-positive oropharyngeal cancer patients.
The results of the present study indicate that p53 and cyclin D1 overexpression are significantly correlated, which is in accordance with previous studies. 13, 34 This may suggest that loss or dysregulation of cell cycle control plays a pivotal role in oral carcinogenesis due to complex interactions between the proteins involved in cell cycle regulation.
Previous reports 49 have concluded that clinical and genetic features of head and neck squamous cell carcinoma are distinct between smokers and nonsmokers, with tumors of nonsmokers containing a lower frequency of common genetic alterations, but the cause of these underlying changes still remains unknown. 50 Focusing on the NSND population with OSCC may provide clues of the path to tumorigenesis, as it is independent of the effect of known carcinogens.
The findings from this study indicate distinct biomarker overexpression in OSCC occurs in different age-groups, tumor sites, and stages. Those with cyclin D1 overexpression appear to be a distinct clinical subgroup of patients who are younger, have later stage cancers presenting in the tongue. Patients with all three of these clinical features (n ¼ 7) were 15 times more likely to have cyclin D1 overexpression. There was no significant statistical association with survival; however, these patients did trend toward better survival, when compared to all other patients with cyclin D1 overexpression (Figure 2(d) ). A link between young NSND patients and the overexpression of p16 in their tumors has also been demonstrated; however, further investigations are still needed to correlate this biomarker overexpression with clinical attributes of disease and the association with HPV. In particular, it is now necessary to undertake quantitative real-time PCR to corroborate the IHC findings for each biomarker in the present study and, most importantly, assess the significance of our p16 IHC results.
